
TLSI Stock Forecast & Price Target
TLSI Analyst Ratings
Bulls say
TriSalus Life Sciences is attractive because TriNav’s PEDD platform is showing commercial traction in a large, underpenetrated liver embolization market, where management estimates it has only about 10% share and 2025 revenue reached $45.2M, up 53% YoY. The company’s outlook is further supported by 2Q26 revenue of $11.4M, a 28% sequential rebound, reiterated FY26 guidance of $54M-$57M, and gross margin expansion to 86.8%, suggesting temporary sales-force disruption is giving way to operating leverage. Beyond liver, the pending TriNav Advance filing, adjacent indications such as UAE and thyroid, and a PEDD-enabled immunotherapy pipeline create multiple paths to expand the addressable market from roughly $480M toward the multibillion-dollar range.
Bears say
TriSalus Life Sciences is viewed negatively because its revenue base is still concentrated in TriNav, leaving the company highly exposed to slower-than-expected device adoption, limited physician awareness, and reimbursement that is revised annually. The recent commercial reset, including more than doubling the sales force, produced only limited productivity by the end of May 2026, while 1Q26 revenue fell 2.9% YoY to $8.9M and FY26 guidance was cut to $54M-$57M from $60M-$62M after the TriNav Advance FDA delay. Its longer-term thesis also carries meaningful execution risk: the PEDD evidence base remains largely retrospective and single-center, the bear case excludes the roughly $800M GAE opportunity, and the company is not yet profitable, raising dilution risk.
This aggregate rating is based on analysts' research of TriSalus Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
TLSI Analyst Forecast & Price Prediction
Start investing in TLSI
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About TriSalus Life Sciences Inc (TLSI) Forecast
TLSI Analyst Forecast & Price Prediction
Start investing in TLSI
Order type
Buy in
Order amount
Est. shares
0 shares